Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024141 (systemic lupus erythematosus)
 44,322 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Antibodies against ribosomal phosphoproteins (anti-P antibodies) are found in about 10% of patients with systemic lupus erythematosus (SLE). Using an ELISA with a synthetic peptide for screening and an immunoblotting technique as a confirmation test for detection of these antibodies, we found 16 positive patients among 946 sera sent to our reference laboratory for anti-DNA determination. All 12 patients on which we could obtain clinical data had clearcut SLE, fulfilling 6 ARA criteria on average. Skin symptoms were observed more frequently in anti-P positive than in anti-P negative patients with SLE. We also tested 56 sera from 54 patients with well defined SLE during monosymptomatic exacerbations and found an identical frequency of about 10% of anti-P antibodies in groups of patients with different types of exacerbation, including psychosis. A retrospective analysis of 9 patients followed 3-10 years showed that they all were already positive for anti-P at the onset of disease. In total these patients showed 15 major peaks in anti-P levels (defined as at least a 4-fold rise in titer in a period of 3 months). Five of the fluctuations in anti-P levels were paralleled by fluctuations in anti-DNA levels. In 6/15 cases, peaks of anti-P levels were accompanied by an exacerbation of SLE, but only 2 peaks of anti-P levels were already detectable before the onset of the exacerbation. In addition, 6 other exacerbations occurred in the absence of major anti-P rises in the preceding 3 months. Therefore, quantitative determinations of anti-P have at most a limited practical value in the followup of patients with SLE.
 ...
PMID:Diagnostic value of antibodies against ribosomal phosphoproteins. A cross sectional and longitudinal study. 192 Mar 7

Raynaud's phenomenon affects most patients who have mixed connective tissue disease (MCTD) and frequently represents the initial manifestation of the disease. It is the cutaneous symptom of a systemic vasculopathy that is characterized by intimal fibrosis and blood vessel obliteration that frequently leads to visceral involvement, particularly pulmonary hypertension. An association between Raynaud's phenomenon and the characteristic autoantibody in MCTD, anti-U1-RNP (ribonucleoprotein), is found across the spectrum of rheumatic diseases, including undifferentiated connective tissue disease, scleroderma, and systemic lupus erythematosus. Capillary nailfold examination represents a valuable tool to identify patients who are at risk for MCTD. The goal in the therapy of Raynaud's phenomenon in MCTD is to decrease the frequency of attacks, to prevent digital ulceration, and to limit progressive vascular damage. Therapeutic regimens include the traditional use of calcium channel blockers and novel vascular therapies.
 ...
PMID:Raynaud's phenomenon in mixed connective tissue disease. 1608 19

Juvenile systemic lupus erythematosus (JSLE) is an autoimmune-mediated multiorgan disease. The cutaneous manifestation is one of the most common initial presentations in JSLE. A typical lesion is a facial malar rash, but a patient may sometimes present with nonclassical lesions. Herein, we report two cases of JSLE with similar persistent scaly ear rashes as the heralding cutaneous symptom preceding systemic symptoms. Identifying this atypical and underestimated cutaneous rash in juvenile patients might help the clinician make the correct diagnosis and provide earlier intervention, which may help prevent disease progression.
 ...
PMID:Scaly ear rash as the herald of a young girl with juvenile systemic lupus erythematosus. 2234 71